Arlin 2 mg/ml is a parenteral formulation of Linezolid, belonging to the oxazolidinone class of antibiotics. It is a synthetic, broad-spectrum antibacterial agent designed to target Gram-positive aerobic bacteria, select Gram-positive anaerobes, and certain Gram-negative bacteria. Arlin 2 mg/ml is commonly used in serious hospital-acquired infections, especially those caused by drug-resistant pathogens like vancomycin-resistant Enterococcus faecium (VRE) and methicillin-resistant Staphylococcus aureus (MRSA).
It is available as an intravenous solution for patients who cannot take oral therapy, and can be transitioned seamlessly to oral Linezolid without dose adjustment due to its high oral bioavailability (~100%).
রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন
Arlin 2 mg/ml is indicated for the treatment of:
Vancomycin-Resistant Enterococcus faecium (VRE) infections, including concurrent bacteremia
Nosocomial pneumonia caused by Staphylococcus aureus (MSSA & MRSA) or Streptococcus pneumoniae, including multi-drug resistant strains
Complicated skin and soft tissue infections, including diabetic foot infections (without osteomyelitis) caused by S. aureus (MSSA & MRSA), Streptococcus pyogenes, or Streptococcus agalactiae
Uncomplicated skin and soft tissue infections caused by S. aureus (MSSA) or Streptococcus pyogenes
Community-acquired pneumonia, including concurrent bacteremia, caused by S. pneumoniae (multi-drug resistant strains) or S. aureus (MSSA only)
Oxazolidinone antibiotic (macrolide-like properties)
Arlin 2 mg/ml selectively inhibits bacterial protein synthesis by binding to the 23S rRNA of the 50S subunit of the bacterial ribosome. This prevents the formation of the 70S initiation complex, essential for bacterial translation.
Bacteriostatic against enterococci and staphylococci
Bactericidal against most streptococcal strains
Effective against multi-drug resistant Gram-positive bacteria
Adults and Adolescents (≥12 years):
Complicated skin infections / Community-acquired pneumonia: 600 mg IV every 12 hours, 10–14 days
Nosocomial pneumonia / VRE infections: 600 mg IV every 12 hours, 14–28 days
Uncomplicated skin infections: 400–600 mg IV every 12 hours, 10–14 days
Pediatric Patients:
Birth to 11 years: 10 mg/kg IV every 8–12 hours depending on age and infection type
Neonates (<7 days): 10 mg/kg IV every 12 hours; may adjust to every 8 hours if needed
Administration Notes:
IV infusion: Administer over 30–120 minutes; do not mix with other additives or use in series connections
Oral switch: No dose adjustment required due to 100% bioavailability
Monoamine oxidase inhibition: Arlin 2 mg/ml is a reversible, nonselective MAO inhibitor
Adrenergic agents: May enhance pressor response; start with reduced doses
Serotonergic agents: Risk of serotonin syndrome; monitor for cognitive changes, hyperreflexia, and hyperpyrexia
Hypersensitivity to Linezolid or components
Use with MAO inhibitors (within 2 weeks)
Uncontrolled hypertension, pheochromocytoma, thyrotoxicosis, carcinoid syndrome
Concomitant use with certain adrenergic or serotonergic drugs (e.g., pseudoephedrine, SSRIs, triptans, meperidine)
Common: Diarrhea, headache, nausea
Other reported: Oral/vaginal candidiasis, hypertension, dyspepsia, abdominal pain, pruritus, tongue discoloration
Rare: Convulsions, visual disturbances, serotonin syndrome
Monitor for recurrent nausea, vomiting, unexplained acidosis
Watch for signs of serotonin syndrome with serotonergic drugs
Ophthalmic evaluation recommended for visual changes
Convulsions may occur in patients with seizure history or risk factors
Pregnancy Category C: Use only if potential benefits outweigh risks
Unknown excretion in human milk; exercise caution while nursing
Store at 15–30°C, protected from light and moisture
Keep out of reach of children.
Login Or Registerto submit your questions to seller
No none asked to seller yet